NCT05069688View on ClinicalTrials.gov

Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Pediatric HIV InfectionTuberculosis Infection
Interventions
DRUG

rifampicin

Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety

Trial Locations (1)

Unknown

RECRUITING

University College Hospital/ University of Ibadan, Ibadan

All Listed Sponsors
collaborator

APIN Public Health Initiatives

UNKNOWN

collaborator

University of Cape Town

OTHER

lead

Brigham and Women's Hospital

OTHER